Last updated: February 6, 2026
This case involves patent infringement allegations related to generic pharmaceuticals. Par Pharmaceutical Inc. (plaintiff) accused Breckenridge Pharmaceutical Inc. (defendant) of infringing on patents protecting Par's medication formulations.
Case Timeline and Procedural Status
- Filed: August 14, 2013, in the District of New Jersey.
- Key filings: Complaint for patent infringement and preliminary injunction motions.
- Disposition: The case was settled prior to trial in late 2014, with terms undisclosed.
Legal Claims and Patent Rights
- Par alleged Breckenridge infringed its U.S. Patent Nos. 8,448,950 and 8,444,814.
- The patents cover specific formulations of controlled-release oxycodone medications.
- Par sought injunctive relief, damages, and attorneys' fees.
Defendant’s Response and Defenses
- Breckenridge challenged the validity of Par’s patents, asserting obviousness and lack of patentability.
- The defendant also argued non-infringement, claiming its product design did not violate the patents' scope.
Key Legal Issues
- Patent validity: Whether Par’s patents meet the requirements under 35 U.S.C. § 103 (obviousness).
- Infringement: Whether Breckenridge’s product falls within the scope of Par’s patent claims.
- Injunctive relief: Whether to grant a preliminary or permanent injunction.
Outcome and Settlement
- The case was settled confidentially in late 2014.
- No final judgment or court ruling was published.
- Settlement likely included licenses or monetary agreements, typical in pharmaceutical patent disputes.
Implications for Industry
- Reinforces the importance of patent validity and infringement defense in pharmaceutical patent litigation.
- Demonstrates the trend of early settlement in patent disputes, especially when patent validity is contested.
- Highlights ongoing legal risks for generic manufacturers infringing on innovator patents.
Analysis
This case exemplifies typical patent enforcement strategies within the pharmaceutical sector. Par relied on patent rights to protect its formulations against entry by generic competitors. Breckenridge contested patent validity, a common defense rooted in obviousness and prior art challenges. Settlement prior to trial aligns with industry practice, reducing lengthy litigation costs and uncertainty.
Key Takeaways
- Patent validity remains a central battleground in pharmaceutical patent litigation.
- Settlements frequently resolve disputes before judicial rulings, affecting licensing negotiations.
- Generic companies often challenge patent scope and validity to avoid infringement liability.
- Patent holders should proactively enforce rights while preparing for validity defenses.
- The case underscores the significance of comprehensive patent prosecution and strategic patent portfolio management.
FAQs
- What are the typical grounds for patent invalidity in pharmaceutical disputes?
Obviousness, prior art invalidation, lack of novelty, and insufficient disclosure are common grounds.
- How does settlement influence patent litigation outcomes in pharma cases?
Settlements terminate disputes without adverse rulings, often leading to licensing or monetary agreements.
- Why do generic companies challenge patents instead of designing around them?
Patent challenges can block or delay market entry; designing around may be complex or unfeasible in some formulations.
- What role does patent scope play in infringement cases?
Broader claims increase infringement risk; narrow claims limit patent enforceability but reduce infringement likelihood.
- How do courts assess patent validity?
Courts analyze prior art, patent specifications, and legal standards for obviousness, novelty, and written description.
Sources
[1] Docket records and filings from U.S. District Court, District of New Jersey, case No. 1:13-cv-01114.
[2] Court rulings and public case summaries from legal research databases such as PACER and Westlaw.
